Loading
Inhibrx Biosciences, Inc. Stock: price and insider trades · United States
3 insiders bought €5.5M of shares over the last 90 days, the latest by Lappe Mark, filed 14 Oct 2026.
Insider Decl.
74
Thresholds
n/a
Buy Volume
€16M
47 ops. · all time
Sell Volume
€10M
4 ops. · all time
Who traded when
BuySaleMark Lappe15 buys
Jon Faiz Kayyem6 buys
Viking Global Investors LP3 sales
Douglas Forsyth1 buy
Kimberly Manhard1 sale
Since the insiders bought
- -10.2%Entry US$109.35 · Close 21 Oct 2026 US$98.19
- -13.0%Entry US$112.86 · Close 21 Oct 2026 US$98.19
- -13.0%Entry US$112.86 · Close 21 Oct 2026 US$98.19
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Inhibrx Biosciences, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$266.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$95.30
Analyst consensus
3 analystsStrong buy
US$230.00Target US$266.67(+180%)US$325.00
Income statement
RevenueUS$1.3M
EBITDA-US$125.4M-9644% margin
Net income-US$140.1M-10773.5% margin
Valuation
PER (forward)-10.9x
Beta3.82
Balance sheet & cash
Market capUS$1.4B
Total debtUS$107M
Free Cash Flow-US$129.8M
Profitability & ownership
ROE-1773.6%
ROA-43.6%
% insiders23.1%
% institutions90.7%
Last declaration on 14 October 2026
Declarations74 total
2,470 shares@ US$84.07070.016% mcap3.7% of flowCommon StockSEC:0001366074-26-000006:0
Canonical exit: 12 Jan 2027 (T+90)
2,470 shares@ US$84.99920.016% mcap3.7% of flowCommon StockSEC:0001366074-26-000006:1
Canonical exit: 12 Jan 2027 (T+90)
100 shares@ US$85.760.0007% mcap0.2% of flowCommon StockSEC:0001366074-26-000006:2
Canonical exit: 12 Jan 2027 (T+90)
2,449 shares@ US$84.07070.016% mcap3.6% of flowCommon StockSEC:0001366074-26-000006:3
Canonical exit: 12 Jan 2027 (T+90)
2,451 shares@ US$84.99920.016% mcap3.7% of flowCommon StockSEC:0001366074-26-000006:4
Canonical exit: 12 Jan 2027 (T+90)
1,500 shares@ US$98.88030.010% mcap3.0% of flowCommon StockSEC:0001366074-26-000004:2
Canonical exit: 27 Dec 2026 (T+90)
3,000 shares@ US$101.7020.021% mcap6.2% of flowCommon StockSEC:0001366074-26-000004:3
Canonical exit: 27 Dec 2026 (T+90)
3,324 shares@ US$98.86590.022% mcap6.7% of flowCommon StockSEC:0001366074-26-000004:0
Canonical exit: 24 Dec 2026 (T+90)
2,176 shares@ US$99.59880.015% mcap4.4% of flowCommon StockSEC:0001366074-26-000004:1
Canonical exit: 24 Dec 2026 (T+90)
5,000 shares@ US$100.000.037% mcap12.0% of flowCommon StockSEC:0001366268-26-000011:0
Canonical exit: 22 Dec 2026 (T+90)
5,000 shares@ US$100.000.037% mcap11.9% of flowCommon StockSEC:0001366268-26-000006:0
Canonical exit: 15 Dec 2026 (T+90)
500 shares@ US$105.050.0039% mcap12.4% of flowCommon StockSEC:0001202094-26-000006:2
500 shares@ US$110.260.0040% mcap13.0% of flowCommonSEC144:0001959173-26-006953
500 shares@ US$111.7750.0041% mcap13.1% of flowCommonSEC144:0001959173-26-006886
500 shares@ US$115.7950.0040% mcap13.6% of flowCommonSEC144:0001959173-26-006844
500 shares@ US$115.140.0040% mcap13.5% of flowCommonSEC144:0001959173-26-006805
2,500 shares@ US$114.64690.019% mcap58.3% of flowCommon StockSEC:0001240801-26-000004:0
Canonical exit: 7 Dec 2026 (T+90)
9,681 shares@ US$112.28190.072% mcap27.2% of flowCommon StockSEC:0001366074-26-000002:5
Canonical exit: 7 Dec 2026 (T+90)
5,000 shares@ US$113.5160.038% mcap13.4% of flowCommon StockSEC:0001366268-26-000004:0
Canonical exit: 7 Dec 2026 (T+90)
5,895 shares@ US$99.29480.039% mcap14.6% of flowCommon StockSEC:0001366074-26-000002:0
Canonical exit: 7 Dec 2026 (T+90)
6,605 shares@ US$100.63880.044% mcap16.6% of flowCommon StockSEC:0001366074-26-000002:1
Canonical exit: 7 Dec 2026 (T+90)
1,100 shares@ US$107.12390.0078% mcap2.9% of flowCommon StockSEC:0001366074-26-000002:2
Canonical exit: 7 Dec 2026 (T+90)
500 shares@ US$108.2350.0036% mcap1.4% of flowCommon StockSEC:0001366074-26-000002:3
Canonical exit: 7 Dec 2026 (T+90)
1,219 shares@ US$111.88050.0090% mcap3.4% of flowCommon StockSEC:0001366074-26-000002:4
Canonical exit: 7 Dec 2026 (T+90)
16,315 shares@ US$32.254.7% of flowCommon StockSEC:0000905148-25-003555:1
25 of 74 declarations
About Inhibrx Biosciences, Inc.
Purchases fill almost the whole Inhibrx Biosciences, Inc. record: 31 purchases worth EUR 9.5 million (median EUR 190,438), or 94% of market trades, against 2 sales. The larger, EUR 8,540,605, dates from October 7, 2025 and comes from Viking Global Investors LP. The other, EUR 45,508, is by director Kimberly Manhard on September 15, 2026.
Mark Lappe, Chief Executive Officer, signed 20 filings, 19 of them purchases, including EUR 934,386 on September 8, 2026. Director Jon Faiz Kayyem made the two largest purchases: EUR 1,045,567 on May 31, 2024 and EUR 780,874 on June 5, 2024. From August 20 to September 12, 2024, 4 insiders bought EUR 1,560,463 in total. Across the full history, 27 purchase filings are classed as clustered.
Read moreShow less
The US healthcare company is listed on Nasdaq at USD 1.4 billion, and 23.1% of its capital is in insiders' hands. It published 46 filings from 9 filers between May 30, 2024 and October 14, 2026: 20 in 2024, 2 in 2025 and 24 in 2026. The last twelve months gather 24 of them, with 19 purchases. The publication delay is 1 day in median. For 12 purchases the 90-day median is -6%, with 25% positive (stored past results, not a forecast).
